PARK8 Antibody

Primary Antibodies

Blue Ice

286 kDa

Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

None

This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Supplied in PBS with 0.09% (W/V) sodium azide.

This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).

Leucine-rich repeat serine/threonine-protein kinase 2

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.